# Cardiol Therapeutics (CRDL) — Earnings

CRDL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/crdl/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2025 |
| Period end | Sep 30, 2025 |
| EPS actual | −$0.09 |
| EPS estimate | −$0.07 |
| EPS surprise | −20.56% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Nov 13, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1702123/000110465925111354/tm2530953d1_6k.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2025 | Nov 13, 2025 | −$0.07 | −$0.09 | -20.56% | — | — |
| Q2 2025 | Aug 14, 2025 | −$0.08 | −$0.07 | 9.03% | — | — |
| Q1 2025 | May 14, 2025 | −$0.08 | −$0.07 | 13.02% | — | — |
| Q4 2024 | Mar 31, 2025 | −$0.09 | −$0.07 | 21.11% | — | — |
| Q3 2024 | Nov 14, 2024 | −$0.09 | −$0.13 | -41.19% | — | — |
| Q2 2024 | Aug 12, 2024 | −$0.10 | −$0.07 | 29.24% | — | — |
| Q1 2024 | May 14, 2024 | −$0.09 | −$0.10 | -16.99% | — | — |
| Q4 2023 | Apr 1, 2024 | −$0.09 | −$0.09 | 0.00% | — | — |
| Q3 2023 | Nov 14, 2023 | −$0.09 | −$0.07 | 25.03% | — | — |
| Q2 2023 | Aug 10, 2023 | −$0.09 | −$0.09 | 4.03% | — | — |
| Q1 2023 | May 15, 2023 | −$0.08 | −$0.08 | 0.00% | — | — |
| Q4 2022 | Mar 29, 2023 | −$0.06 | −$0.09 | -50.00% | — | — |
| Q3 2022 | Nov 10, 2022 | −$0.10 | −$0.09 | 10.40% | — | — |
| Q2 2022 | Aug 10, 2022 | −$0.10 | −$0.08 | 23.09% | — | — |
| Q1 2022 | May 16, 2022 | −$0.14 | −$0.11 | 17.66% | — | — |
| Q4 2021 | Mar 24, 2022 | −$0.11 | −$0.09 | 21.41% | — | — |
| Q3 2021 | Nov 15, 2021 | −$0.11 | −$0.18 | -64.37% | — | — |
| Q2 2021 | Aug 17, 2021 | −$0.11 | −$0.13 | -14.24% | — | $63,603.33 |

## Frequently Asked Questions

### When did Cardiol Therapeutics (CRDL) last report earnings?

Cardiol Therapeutics last reported on Nov 13, 2025, covering fiscal Q3 2025.

### Did CRDL beat earnings estimates?

No. Cardiol Therapeutics reported EPS of −$0.09 for Q3 2025 against a −$0.07 estimate — a 20.56% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).